Get 250+ investors tailored to your startup

Invest in your industry and stage
Emails & contact info included
Excel and CSV export
Automatically

Trusted by 3,000+ startups

Top 10 Medical VC (Venture Capital) Funds in Iceland in February 2025

Last updated: Feb 2025 A list of 10 VC (Venture Capital) funds that invest in Medical startups based in Iceland. We rank investors based on the number of investments they made in Medical companies from Iceland. We update this investor list every month.

Top 10 Medical VC (Venture Capital) Funds in Iceland in February 2025

Investor	Medical Iceland investments
New Business Venture Fund	8
Novator	3
Silicon Valley Bank	2
Frumtak Ventures	2
ABC Ventures	1
Brunnur Ventures	1
Probiocon	1
Wellington Partners	1
Flerie Invest	1
Asabys Partners	1

Find investors that fund startups like yours. Automatically.

Our algorithm will find investors that invest in your industry, stage, and geography.

Investor list

The New Business Venture Fund is an evergreen investment fund that actively contributes to the development and growth of the Icelandic economy by investing in promising innovation and start-up companies.The New Business Venture Fund invests at seed and early stage in promising growth companies with great business ideas and strong management anddevelopment teams.The New Business Venture Fund is a state owned investment fund intended to strengthen and develop the Icelandic venture capital market along with promoting startups and business in Iceland thus encouraging economic growth.

Investment focus

Software, Health Care, Medical
Seed, Funding Round, Series A
Iceland, United States, China

Portfolio highlights

HorseDay — HorseDay is a mobile application to track horse activities.
Spectaflow — Spectaflow is a SaaS solution for accommodations businesses focused on improving housekeeping and maintenance workflows
PayAnalytics — PayAnalytics, a leading pay equity and workforce analytics solution, aids companies in closing pay gaps and fostering workplace equity. Ensure compliance with pay transparency regulations, assess wage disparities, and analyze workforce demographics conveniently.

Novator is an alternative investment firm founded and led by the international investor and entrepreneur Thor Bjorgolfsson.Novator's investment portfolio is focused around following sectors: Telecommunications, Pharmaceuticals, IT and Renewable Energy. In addition, Novator operates a Private Equity Fund and a Credit Opportunities Fund.Novator focuses on developing strong management teams in each of its portfolio companies. While granting them the autonomy to create value, Novator maintains a supervisory role, principally through representation on the Boards of its investee companies. Novator differentiates itself from many other private equity companies in concentrating on complex situations, either by virtue of their structure or their cross-border nature. To create value, Novator undertakes the restructuring or "de-risking" of investment opportunities through re-financing, combining acquired assets with existing businesses, through sale to strategic or financial buyers, or through flotation. Novator's investment portfolio is focused around four main sectors:Telecommunications, Pharmaceuticals, IT and Renewable Energy.

Investment focus

Software, E-Commerce, Online Games
Funding Round, Series B, Series C
United Kingdom, United States, Iceland

Portfolio highlights

Nord Security — Nord Security is the leader in the field of online privacy and security. Our security tools have earned praise from respected experts and tech outlets.
Better.com — Better Mortgage Corporation is a direct lender dedicated to providing a fast, transparent digital mortgage experience backed by superior customer support.
Steel City Interactive — Steel City Interactive develops gaming.

Silicon Valley Bank is the financial partner of the innovation economy; helping individuals and investors in the innovation ecosystem achieve extraordinary outcomes.

Investment focus

Software, Health Care, Biotechnology
Debt Financing, Series B, Series A
United States, United Kingdom, Canada

Portfolio highlights

Chimerix — Chimerix is developing novel antiviral therapeutics with the potential to transform patient care in multiple settings, including transplant, oncology, acute care and global health.The company's lead candidate, CMX001, is being developed as a potential broad spectrum antiviral agent for the treatment of life-threatening double-stranded DNA(dsDNA) viral diseases. Over 350 people have received CMX001 to date, with a growing body of evidence supporting the drug's antiviral activity in humans.Clinical studies of CMX001 include an ongoing Phase 2 study of the prevention/control of cytomegalovirus (CMV) in hematopoietic stem cell transplant patients (CMX001-201), a Phase 2 study being initiated for the treatment of adenovirus (AdV) infection in pediatric and adult hematopoietic stem cell transplant patients (CMX001-202), and an Open-Label Study (CMX001-350) for the treatment of any of 12 different dsDNA viral infections, including AdV, herpes viruses such as CMV, herpes simplex virus and Epstein Barr virus, polyoma viruses such as BK virus and JC virus, and pox viruses. The Open-Label Study builds on Chimerixâ€™s extensive experience working with clinicians at over 55 leading institutions in the United States, Canada, Europe and Israel who have sought CMX001 for the treatment of more than 150 immunocompromised patients under Emergency INDs. CMX001 has been well tolerated in all studies.CMX001 is also being developed as a medical countermeasure in the event of a smallpox release. Chimerix has received significant federal funding for the development of CMX001 as a medical countermeasure against smallpox from the National Institute of Allergy and Infectious Diseases.Chimerix's second clinical-stage antiviral compound, CMX157, a potent nucleoside analogue with in vitro activity against HIV and hepatitis B, has the potential to directly address several limitations of current HIV therapies. Chimerix is developing CMX157 for the treatment of HIV infection including those caused by multi-drug resistant viruses. A Phase 1 clinical study has been completed demonstrating that the compound is well tolerated and that the active antiviral, TFV-PP, was measurable in peripheral blood mononuclear cells (PBMCs) after a single dose and remained detectable for six days, indicating that it may be suitable for once-weekly dosing.Led by a world-class antiviral drug development team, Chimerix is also leveraging the company's extensive chemical library to pursue new treatments for hepatitis C virus, flu, malaria and other global public health needs.
Castelion — We are a modern defense production company building the next generation of military hypersonic, vehicle, and strike systems to deter future wars.
TScan Therapeutics — Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien velit, aliquet eget commodo nec, auctor a sapien. Nam eu neque vulputate diam rhoncus faucibus. Curabitur quis varius libero.

At Frumtak Ventures, we champion founders who have demonstrated early traction and have potential to become global leaders in their space. We take a concentrated, high-conviction, and high-involvement approach to investing and dedicate ourselves to collaboratively work with our portfolio companies from the seed stage through IPO. Our initialticket size usually ranges from €1 million to €3 million.

Investment focus

Software, Information Technology, Enterprise Software
Seed, Funding Round, Series A
Iceland, United States, United Kingdom

Portfolio highlights

PLAIO — The only AI-assisted decision-making platform developed for pharmaceutical manufacturing
Moombix — Join us for the launch of our advanced learning platform for online music lessons
Treble — We develop next generation sound simulation and spatial audio technology for digital twins and virtual worlds.

ABC Ventures operates as an investment firm.

Investment focus

Water, Medical, Health Care
Pre-Seed, Series A
India, Iceland

Portfolio highlights

Polka Pop — Polka Pop is India's first brand to serve naturally flavored sparkling water with zero calories and no added sugar. Supporting a sustainable lifestyle choice, this healthy drink is available in four flavors, i.e. lemon-lime, orange, peach, and cranberry. The fizz makes this the best mix for cocktails and mocktails.
EpiEndo Pharmaceuticals — Welcome to EpiEndo Pharma | Developing epithelial barrier enhancing drugs to treat chronic respiratory diseases

Brunnur Ventures is a top venture capital firm in Iceland for startups with high-growth potential.

Investment focus

Software, SaaS, Gaming
Seed, Series A, Funding Round
Iceland, United States, Denmark

Portfolio highlights

AviLabs — AviLabs specializes in software development in aviation.
Laki Power — We supply power grid operators with advanced high-voltage line monitoring stations that enable them to optimise performance, safety and cost.
Porcelain Fortress — Porcelain Fortress was founded by a small band of romantics in the summer of 2016 in Reykjavik, Iceland.

Probiocon is a consulting company offering comprehensive services for pharmaceutical and biotechnological companies. We give advice and support for all kind of corporate development activities (services) needed for biotech and pharma companies, including but not limited to Corporate Financing, Licensing & Partnering, Merger & Acquisition,and Corporate Organisation.Their vision is to provide optimized and cost-effective solutions to the special needs of companies developing biopharmaceutical compounds.

Investment focus

Medical, Consulting, Health Care
Seed
Iceland

Portfolio highlights

3Z Pharmaceuticals — 3Z Pharmaceuticals provides research services intended to provide drug development services. It offers drug screening on sleep and epilepsy assays that helps in the development of drugs used to treat neurological disorders, enabling patients to get multiple drug efficacy and toxicity assays.Karl Karlsson and Haraldur Thorsteinsson founded 3ZPharmaceuticals in 2008. It based their company on their research on the sleeping patterns of the zebrafish at the Reykjavik University Neurolab in 2006.

Wellington Partners is a venture capital firm that invests in technology and life sciences companies, focusing on Digital Media, Software, Electronics & Photonics, Resource Efficiency, and Biotech/Life Sciences. It is committed to providing outstanding entrepreneurs with the necessary resources to fund their strategies. We typically leadfinancing rounds ranging from € 0.5 million to € 20 million. Depending on the maturity of the company, its own commitment can go as high as € 15 million.Wellington was established in 1998 and has offices in Munich, London, and Zurich.

Investment focus

Health Care, Biotechnology, Medical
Series A, Series B, Funding Round
Germany, United States, United Kingdom

Portfolio highlights

Aignostics — Aignostics is an AI-powered precision diagnostics focused on pathology to assist with drug development and clinical research. Its “explainable” AI overcomes the “black-box” limitations of conventional AI. Based on their patented technology for reverse-engineering the black box, they render diagnostic results explainable in the form of preciseheatmaps and image overlays. These heatmaps allow pathologists to quickly verify the results of the AI, which is crucial, as the pathologist is ultimately responsible for the diagnosis.The company was founded in 2018 and is headquartered in Berlin, Germany.
Sphingotec GmbH — Improving patient outcomes with innovative diagnostics for critical care: Actionable insights in real-time
CorFlow Therapeutics AG — CorFlow Therapeutics is a medtech startup that develops proprietary technologies for diagnosis and treatment of microvascular obstructions in heart attack patients. The CorFlow technologies enable interventional cardiologists to diagnose and treat MVO in severe heart attack patients thereby potentially reducing the short- and long-term complicationrates in these patients.

Flerie is an active long-term life science investor, focusing on biotech and pharmaceutical investments globally.

Investment focus

Biotechnology, Health Care, Medical
Series A, Funding Round, Series B
Sweden, Israel, Iceland

Portfolio highlights

Microbiotica — Microbiotica is a developer of human microbiome therapeutics intended to discover and develop live bacterial therapeutics and biomarkers. The company's therapeutics identify gut bacteria linked to phenotype with unprecedented precision, enabling researchers to phenotype before testing of candidate bacteria in advanced human in vitro and invivo models.
Synerkine Pharma — Synerkine Pharma. Connecting Cytokines for the benefit of patients.
Vitara Biomedical — Vitara Biomedical has developed a therapeutic platform to support premature infants. Vitara Biomedical's platform was inspired by natural physiological processes to transform neonatal care.

Asabys Partners is a venture capital firm that invests across the board in human healthcare. The company is active in the health-tech and biopharma industries and aims to invest in Spain and abroad in innovative and transformative technologies. Asabys Partners are motivated by the idea of pushing the boundaries of science and medicine. This is donethrough the sourcing and financing of the most disruptive technologies, and through the collaboration with the best internal and external talents of our industry.

Investment focus

Biotechnology, Medical Device, Health Care
Series A, Seed, Series B
Spain, France, Belgium

Portfolio highlights

Quibim — Leading radiomics company pioneering quantitative imaging biomarkers and medical applications in precision medicine.
Medlumics — Medlumics is a medical device start-up born in 2009 from a compromise with improving human living standards by means of technology.
INBRAIN Neuroelectronics — We are scientists, doctors, techies and humanity lovers, with the mission of building neuroelectronic interfaces to cure brain disorders.

Investors by industry

Artificial intelligence